New drug cocktail shows promise against esophageal cancer in early trial
NCT ID NCT07374003
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two immune-boosting drugs (ipromlimab and tuvonralimab) with standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. The study involves 62 participants and is currently active but not recruiting. The main goal is to see how many patients have no cancer cells left in their surgical sample.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipromlimab and tuvonralimab (immune-boosting drugs) plus albumin-bound paclitaxel and nedaplatin (chemotherapy)
- What this could lead to
- If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with esophageal cancer.
- What could go wrong
- This is an early-phase, single-arm study with only 62 participants, so results may not apply broadly. The drug combination may cause significant side effects and may not work better than standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sub-i
Guangdong, GUANGZHOU, 510000, China